Marcílio Jorge Fumagalli

Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial

Marcílio Jorge Fumagalli, Anna Kaczynska, Marius Allombert, Ágata Lopes-Ribeiro et autres

Abstract RIO is an ongoing phase 2 double-blind randomized placebo-controlled human trial. Sixty-eight adult men living with human immunodeficiency virus (HIV), who were predominantly white and initiated antiretroviral therapy (ART) during primary or early-stage infection, underwent treatment interruption and were randomly assigned …

us, fr, br, gb, dk (code pays fourni par la source)

Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial

Ming Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, Simon Collins et autres

Abstract Background HIV-specific broadly neutralising antibodies (bNAbs) can maintain viral control after interrupting antiretroviral therapy (ART). We investigated the duration and efficacy of Fc-engineered long-acting bNAbs (LS-bNAbs) in maintaining ART-free HIV control compared with placebo. Methods RIO is a 1:1 randomised double-blind …

gb, us, hk, au, no, dk (code pays fourni par la source)

PRISM-Seq: An Ultra-sensitive Sequencing Approach For Mapping Lentiviral Integration Sites

Virender Kumar Pal, Marie Canis, Emily Stone, Nathan L. Board et autres

Retroviral integration into host genomes is central to both HIV-1 persistence and the safety and function of lentiviral vectors used in gene and cell therapies. However, existing integration site assays remain limited by sensitivity, input requirements, and analytical complexity, and none have …

us, ca, de (code pays fourni par la source)

Transcription of HIV-1 is heterogenous among authentic latent CD4+ T cell clones

Cíntia Bittar, Ana Rafaela Teixeira, Thiago Y. Oliveira, Gabriela S. Silva Santos et autres

Antiretroviral therapy suppresses HIV-1 infection but fails to eliminate a reservoir of intact latent proviruses that reside primarily in CD4+ T cells. The lack of precise understanding of the latent compartment has made it challenging to develop curative strategies for HIV-1 infection. …

us, br, de (code pays fourni par la source)

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial

Marcílio Jorge Fumagalli, Anna Kaczynska, Marius Allombert, Ágata Lopes-Ribeiro et autres

Abstract RIO is an ongoing double blind randomized placebo controlled human trial in which participants that started antiretroviral therapy (ART) during primary or early-stage infection underwent treatment interruption and were randomly assigned to a group receiving one or two doses of two …

us, fr, br, gb, au, dk (code pays fourni par la source)

HIV-1 expression is heterogeneous among clones of CD4+ T cells carrying authentic intact latent proviruses

Cíntia Bittar, Ana Rafaela Teixeira, Thiago Y. Oliveira, Gabriela S. Silva Santos et autres

Abstract Antiretroviral therapy suppresses HIV-1 infection but is not curative because it fails to eliminate a reservoir of intact latent proviruses that reside primarily in CD4+ T cells. This compartment is composed of rare T cells that predominantly express memory and effector …

us (code pays fourni par la source)

Time to HIV Rebound after Antiretroviral Therapy Interruption: A Double-Blind Randomised Placebo-Controlled Trial of Long-Acting Broadly Neutralising Antibodies; the RIO Trial

Ming Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, Simon Collins et autres

gb, us, hk, ca, dk, fr (code pays fourni par la source)

PP1.15 – 00056 Transcriptional analysis of clonal cultures of CD4+ T cells harboring real intact provirus from people living with HIV

Cíntia Bittar, André A. Teixeira, Thiago Y. Oliveira, Marcílio Jorge Fumagalli et autres

Pathophysiology of chikungunya virus infection associated with fatal outcomes

William Marciel de Souza, Marcílio Jorge Fumagalli, Shirlene Telmos Silva de Lima, Pierina Lorencini Parise et autres

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes acute, subacute, and chronic human arthritogenic diseases and, in rare instances, can lead to neurological complications and death. Here, we combined epidemiological, virological, histopathological, cytokine, molecular dynamics, metabolomic, proteomic, and genomic analyses to …

us, br, Sao Tomé-et-Principe, gb, pa (code pays fourni par la source)

Airway epithelial cells and macrophages trigger IL-6-CD95/CD95L axis and mediate initial immunopathology of COVID-19

Thais Fernanda de Campos Fraga‐Silva, Ualter Guilherme Cipriano, Marcílio Jorge Fumagalli, Giseli Furlan Corrêa et autres

Airway epithelial cells (AEC) infected with SARS-CoV-2 may drive the dysfunction of macrophages during COVID-19. We hypothesized that the direct interaction of AEC with macrophages mediated by CD95/CD95L or indirect interaction mediated by IL-6 signaling are key steps for the COVID-19 severe …

br (code pays fourni par la source)

Linear epitope mapping in the E and NS1 proteins of dengue and Zika viruses: Prospection of peptides for vaccines and diagnostics

Víctor Hugo Aquino, Marcílio Jorge Fumagalli, Angélica Silva, Bento Vidal de Moura Negrini et autres

The arrival of the Zika virus (ZIKV) in dengue virus (DENV)-endemic areas has posed challenges for both differential diagnosis and vaccine development. Peptides have shown promise in addressing these issues. The aim of this study was to identify the linear epitope profile …

br, py (code pays fourni par la source)

Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern

Patrick O. Azevedo, Natália Satchiko Hojo-Souza, Lídia Faustino, Marcílio Jorge Fumagalli et autres

The current COVID-19 vaccines protect against severe disease, but are not effective in controlling replication of the Variants of Concern (VOCs). Here, we used the existing pre-clinical models of severe and moderate COVID-19 to evaluate the efficacy of a Spike-based DNA vaccine …

br, us (code pays fourni par la source)